Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
NCT03041025Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of gsk2330811 in diffuse cutaneous systemic sclerosis (dcSSc) (4 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs), Change From Baseline in Hematology Parameters at Day 197 and 4 more. Started Jun 2017; status: completed.
02
Drugs
gsk2330811
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT03041025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041025.